ALNYLAM PHARMACEUTICALS, INC. (ALNY) Free cash flow 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$465.4MFY2025 · since FY2016: -$372.3M → $465.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $465.4M | +1192.7% |
| FY2024 | -$42.6M | -201.5% |
| FY2023 | $41.9M | +106.8% |
| FY2022 | -$613.3M | +14.6% |
| FY2021 | -$718.1M | -4.8% |
| FY2020 | -$685.3M | -63.7% |
| FY2019 | -$418.6M | +39.3% |
| FY2018 | -$689.5M | -41.6% |
| FY2017 | -$487.0M | -30.8% |
| FY2016 | -$372.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice